Icosagen

Icosagen is an Estonia-based, research-driven Contract Research, Development, and Manufacturing Organization (CRDMO) serving the biopharmaceutical and biotechnology sectors. The company operates through an integrated model that combines CRO and CDMO capabilities under one roof, providing a full lifecycle of services for therapeutic biologics. Their core technical offerings include antibody discovery, complex protein production using proprietary QMCF CHO-based technology, stable cell line development, process development, and clinical-grade GMP manufacturing. By keeping discovery, development, and manufacturing within a single, unified team and site, Icosagen aims to improve project traceability, ensure data integrity, and accelerate development timelines by eliminating common tech-transfer bottlenecks.

This approach provides significant value to biopharmaceutical and biotech partners tasked with navigating the challenging path from target identification to clinical candidate selection. By leveraging deep expertise in molecular biology, virology, and bioprocessing, Icosagen helps clients address technical hurdles such as the expression of hard-to-produce membrane proteins and the optimization of antibody-drug conjugates. Their one-site, one-team model serves as a strategic resource for companies seeking to save time and resources while maintaining high scientific rigor and quality control throughout the entire drug development journey. Hundreds of global pharmaceutical companies have utilized these services to advance their therapeutic candidates from early research stages to pre-clinical and early clinical development.